Regorafenib combined with irinotecan as second-line treatment in metastatic gastro-oesophageal adenocarcinomas: results of PRODIGE 58-UCGI35-REGIRI Unicancer randomised phase II study.

Date publication

mai 2025

Journal

ESMO open

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BEN ABDELGHANI Meher , Pr BOUCHE Olivier , Dr HENNEQUIN Audrey

Tous les auteurs :
Samalin E, Evesque L, Turpin A, De La Fouchardiere C, Khemissa-Akouz F, Bouché O, Muller M, Dermeche S, Botsen D, Tougeron D, Zaanan A, Ben Abdelghani M, Guardiola E, Dubreuil O, Le Brun Ly V, Hennequin A, Watson S, Sefrioui D, Lecomte T, De Sousa Carvalho N, Hulin A, Crapez E, Castan F, Senellart H

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/40359707

Résumé

Several options have been evaluated in metastatic gastro-oesophageal adenocarcinomas (mGA) after failure of first-line fluoropyrimidine and platinum-based chemotherapy. Regorafenib (REGO), a receptor tyrosine kinase inhibitor, has shown promising activity as second- and third-line treatment of mGA.

Mots clés

irinotecan (IRI), metastatic gastro-oesophageal adenocarcinomas (mGA), regorafenib (REGO)

Référence

ESMO Open. 2025 05 12;10(5):105096